CATX

Perspective Therapeutics Inc

2.78

Oct 05 • 7:32 AM ET +0.02 (0.72%)

Healthcare Medical Devices USA Small AMEX

Peers: NBTX TLX LNTH ABT BSX EW MDT SYK GKOS BMRN

| Held by: VTI IWM VXF IWN VTWO IBB SCHA VHT IWC DFAS

Index	RUT
Market Cap	317.34M
Enterprise Value	84.42M
Income	-116.43M
Sales	0.41M
Book/sh	2.84
Cash/sh	2.08
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	166
IPO	Nov 10, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	774.01
P/B	0.98
P/C	1.34
P/FCF	-
EV/EBITDA	-
EV/Sales	205.91
Quick Ratio	6.61
Current Ratio	6.61
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.33
EPS next Y	-1.03
EPS next Q	-0.24
EPS this Y	30.62%
EPS next Y	-5.31%
EPS next 5Y	11.53%
EPS past 3/5Y	-39.72% -22.26%
Sales past 3/5Y	-56.57% -38.04%
EPS Y/Y TTM	-0.42%
Sales Y/Y TTM	-66.88%
EPS Q/Q	23.29%
Sales Q/Q	-72.07%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	12.39% -10.50%

Insider Own	16.74%
Insider Trans	-2.64%
Inst Own	85.86%
Inst Trans	6.28%
ROA	-33.19%
ROE	-39.57%
ROIC	-35.64%
Gross Margin	-890.95%
Oper. Margin	-28174.08%
Profit Margin	-28467.97%
SMA20	0.18%
SMA50	-6.45%
SMA200	-22.97%
Trades

Shs Outstand	114.09M
Shs Float	95.04M
Short Float	24.00%
Short Ratio	13.95
Short Interest	22.81M
52W High	6.16 -54.87%
52W Low	1.96 42.20%
Volatility	5.61% 6.33%
ATR (14)	0.18
RSI (14)	47.51
Beta	1.94
Rel Volume	0.13
Avg Volume	1.63M
Volume	10,579

Perf Week	11.20%
Perf Month	-10.90%
Perf Quarter	-18.71%
Perf Half Y	-36.53%
Perf YTD	1.09%
Perf Year	-23.63%
Perf 3Y	-3.47%
Perf 5Y	-55.16%
Perf 10Y	-61.12%
Recom	1.13
Target Price	12.23
Prev Close	2.76
Price	2.78
Change %	0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-26	Initiated	William Blair	Outperform
Aug-19-26	Initiated	BMO Capital Markets	Outperform	$11
Feb-19-26	Initiated	Piper Sandler	Overweight	$16
Nov-24-25	Resumed	Truist	Buy	$12
Oct-10-25	Initiated	BTIG Research	Buy	$14
Mar-13-25	Initiated	H.C. Wainwright	Buy	$10
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$15
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral	$24 → $5
Oct-24-24	Initiated	UBS	Buy	$20
Oct-01-24	Initiated	Wedbush	Outperform	$25
Sep-25-24	Initiated	Truist	Buy	$21
Jul-25-24	Initiated	BofA Securities	Buy	$24
May-09-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Oct-02-26 11:46AM	Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 (GlobeNewswire)
Sep-14-26 06:16AM	Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors (GlobeNewswire)
Sep-11-26 06:00AM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 (GlobeNewswire)
Aug-10-26 04:44PM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press) +6.00%
04:22PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results (GlobeNewswire)
06:30AM	Loading…
Jul-31-26 06:30AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 06:30AM	Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs (GlobeNewswire)
Jul-17-26 12:22PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)
Jul-08-26 06:30AM	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor (GlobeNewswire)
Jun-03-26 02:06PM	Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial (Proactive)
06:30AM	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study (GlobeNewswire)
May-21-26 05:51PM	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma (GlobeNewswire)
May-18-26 06:30AM	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies (GlobeNewswire)
May-11-26 05:58PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:07PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results (GlobeNewswire)
06:30AM	Loading…
Apr-24-26 06:30AM	Perspective Therapeutics to Provide Several Upcoming Corporate Updates (GlobeNewswire)
Apr-20-26 06:00AM	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting (GlobeNewswire) +8.33%
Apr-02-26 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-17-26 04:45PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the AACR Annual Meeting 2026 (GlobeNewswire) -5.17%
Mar-16-26 04:07PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results (GlobeNewswire)
Feb-17-26 08:42PM	Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress (Insider Monkey)
11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results (GlobeNewswire)
Feb-02-26 08:35AM	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +33.51%
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) -11.03%
Jan-12-26 07:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -15.14%
Jan-09-26 07:00AM	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-25 07:00AM	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-04-25 07:00AM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium (GlobeNewswire) +8.14%
Nov-20-25 07:00AM	Perspective Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) -7.83%
04:27PM	Loading…
Nov-10-25 04:27PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results (GlobeNewswire)
Nov-06-25 07:45AM	Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Nov-04-25 05:25PM	Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates (Zacks) -10.38%
Oct-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming November Conferences (GlobeNewswire)
Oct-29-25 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-24-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-20-25 04:00AM	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025 (GlobeNewswire) -28.95%
Oct-02-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
Sep-15-25 07:00AM	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Sep-04-25 07:00AM	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer (GlobeNewswire)
Sep-03-25 07:00AM	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors (GlobeNewswire)
Aug-26-25 07:00AM	Perspective Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-25 06:50AM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:45AM	Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results (GlobeNewswire)
Aug-12-25 06:05PM	Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.99%
Aug-06-25 05:35PM	electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 07:15AM	Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates (Zacks)
Jul-24-25 12:45PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
12:45PM	Perspective Therapeutics Announces Acceptance of VMT--NET Data for Presentation at the ESMO Congress 2025 (GlobeNewswire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-15-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -7.06%
Jun-21-25 08:00AM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT--NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
May-30-25 05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting (GlobeNewswire) -7.00%
05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT--NET at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-21-25 11:22AM	Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential (Insider Monkey) -13.07%
May-12-25 04:43PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +6.81%
04:36PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Perspective Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP- Positive Solid Tumors (GlobeNewswire)
Apr-23-25 12:25PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) +8.88%
12:25PM	Perspective Therapeutics Announces Acceptance of VMT- -NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire)
07:00AM	Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? (Zacks)
Apr-17-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-11-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Apr-09-25 12:08AM	Is Now The Time To Invest In Perspective Therapeutics (Seeking Alpha) +11.11%
Apr-02-25 09:35AM	Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround (Zacks)
Mar-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-26-25 04:10PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) -8.10%
Mar-17-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Feb-26-25 07:00AM	Perspective Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-21-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 07:00AM	Perspective Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire) +5.67%
Jan-24-25 12:18PM	Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars (Benzinga) +10.47%
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-22-25 07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
Jan-14-25 08:35AM	Perspective Therapeutics provides business updates, strategic priorities (TipRanks) -5.88%
Jan-13-25 08:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:00AM	Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer (GlobeNewswire)
Nov-27-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in December (GlobeNewswire) -6.36%
Nov-26-24 07:00AM	Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital (TipRanks) +19.24%
06:45AM	Perspective Therapeutics downgraded to Neutral from Buy at BofA (TipRanks)
Nov-21-24 07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire) -51.38%
07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire)
Nov-16-24 01:26AM	Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-15-24 04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire) -11.66% -11.68%
04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire)
Nov-12-24 04:37PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.94%
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
Oct-31-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire)
Oct-23-24 07:00AM	Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) -5.65%

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

MBAJohan M. Spoor

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lantheus Alpha Therapy, LLC	10% Owner	Sep 04 '26	Sale	3.15	167,149	526,051	11,273,364	Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 03 '26	Sale	3.11	80,783	250,896	11,440,513	Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 02 '26	Sale	3.11	42,129	131,219	11,521,296	Sep 04 05:00 PM
Lantheus Alpha Therapy, LLC	10% Owner	Aug 31 '26	Sale	3.14	78,145	245,610	11,599,194	Sep 04 04:58 PM
Lantheus Alpha Therapy, LLC	10% Owner	Sep 01 '26	Sale	3.12	35,769	111,574	11,563,425	Sep 04 04:58 PM
Lantheus Holdings, Inc.	10% Owner	Sep 01 '26	Sale	3.12	35,769	111,574	11,563,425	Sep 03 04:54 PM
Lantheus Holdings, Inc.	10% Owner	Aug 31 '26	Sale	3.14	78,145	245,610	11,599,194	Sep 02 04:36 PM
Hunt Jonathan Robert	Chief Accounting Officer	Nov 13 '25	Buy	2.03	11,000	22,295	59,800	Nov 17 08:01 AM
Williamson Robert F III	Director	Nov 12 '25	Buy	2.10	9,498	19,946	9,864	Nov 14 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your Finviz experience